MedAccess was established in November 2017. We were originally formed as The Credit Facility for Access to Medicines, in response to ongoing concerns within the global health community that access to medical supplies in low- and middle-income countries was being impeded by market inefficiencies.
MedAccess was founded by British International Investment (BII), the UK’s development finance institution, with support from the Department for International Development (now replaced by the Foreign, Commonwealth & Development Office (FCDO)) and the Clinton Health Access Initiative (CHAI). MedAccess is a wholly-owned subsidiary of BII.
$200m capital authorised by British International Investment (BII) in preparation for MedAccess’ incorporation.
MedAccess formally incorporated. Michael Anderson begins work as CEO.
Nigel Keen appointed Board Chair. First $100 million of paid-in capital issued by BII.
BII pays in further $100 million capital, taking MedAccess’ capitalisation to $200 million.
Launch of procurement guarantee for UNICEF to accelerate procurement of essential COVID-19 and non-COVID-19 supplies.
UNICEF procurement guarantee for essential COVID-19 and non-COVID-19 products extended by one year.
MedAccess’ 2021-2025 strategy approved by the Board.
Professor Helen Rees OBE appointed Board Chair.